Taiwan · Delayed Price · Currency is TWD Original BioMedicals Statistics
Total Valuation
TPEX:6483 has a market cap or net worth of TWD 772.99 million. The enterprise value is 543.78 million.
| Market Cap | 772.99M |
| Enterprise Value | 543.78M |
Important Dates
The next estimated earnings date is Sunday, August 10, 2025.
| Earnings Date | Aug 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6483 has 66.35 million shares outstanding. The number of shares has increased by 33.68% in one year.
| Current Share Class | 66.35M |
| Shares Outstanding | 66.35M |
| Shares Change (YoY) | +33.68% |
| Shares Change (QoQ) | +1.20% |
| Owned by Insiders (%) | 3.53% |
| Owned by Institutions (%) | 2.64% |
| Float | 60.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.03 |
| P/TBV Ratio | 3.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.25 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.33 |
Financial Position
The company has a current ratio of 17.77, with a Debt / Equity ratio of 0.05.
| Current Ratio | 17.77 |
| Quick Ratio | 17.65 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.14 |
| Interest Coverage | -90.24 |
Financial Efficiency
Return on equity (ROE) is -25.78% and return on invested capital (ROIC) is -16.05%.
| Return on Equity (ROE) | -25.78% |
| Return on Assets (ROA) | -15.06% |
| Return on Invested Capital (ROIC) | -16.05% |
| Return on Capital Employed (ROCE) | -29.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -3.26M |
| Employee Count | 23 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.81% in the last 52 weeks. The beta is 0.09, so TPEX:6483's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -41.81% |
| 50-Day Moving Average | 13.08 |
| 200-Day Moving Average | 12.78 |
| Relative Strength Index (RSI) | 31.80 |
| Average Volume (20 Days) | 45,547 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -78.33M |
| Pretax Income | -75.00M |
| Net Income | -75.00M |
| EBITDA | -74.05M |
| EBIT | -78.33M |
| Earnings Per Share (EPS) | -1.14 |
Balance Sheet
The company has 241.19 million in cash and 11.98 million in debt, giving a net cash position of 229.21 million or 3.45 per share.
| Cash & Cash Equivalents | 241.19M |
| Total Debt | 11.98M |
| Net Cash | 229.21M |
| Net Cash Per Share | 3.45 |
| Equity (Book Value) | 255.25M |
| Book Value Per Share | 3.87 |
| Working Capital | 241.88M |
Cash Flow
In the last 12 months, operating cash flow was -84.11 million and capital expenditures -1.84 million, giving a free cash flow of -85.95 million.
| Operating Cash Flow | -84.11M |
| Capital Expenditures | -1.84M |
| Free Cash Flow | -85.95M |
| FCF Per Share | -1.30 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6483 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.68% |
| Shareholder Yield | n/a |
| Earnings Yield | -9.70% |
| FCF Yield | -11.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |